Synthesis, characterization, anticancer, and antioxidant activity of some new thiazolidin-4-ones in MCF-7 cells
| dc.contributor.author | Isloor, A.M. | |
| dc.contributor.author | Dhanya, D. | |
| dc.contributor.author | Shetty, P. | |
| dc.contributor.author | Malladi, S. | |
| dc.contributor.author | Pai, K.S.R. | |
| dc.contributor.author | Maliyakkal, N. | |
| dc.date.accessioned | 2026-02-05T09:34:53Z | |
| dc.date.issued | 2013 | |
| dc.description.abstract | There are limited studies centring on the potential of thiazolidin-4-ones as anticancer agents. In this study, a new series of 2-(3-substituted-1H- pyrazol-4-yl)-3-(3-substituted-5-sulfanyl-1,2,4-triazol-4-yl)-1, 3-thiazolidin-4-one (4a-o) have been synthesized by cyclo-condensation reaction of 5-substituted-4-[(3-substituted-1H-pyrazol-4-ylmethylidene)amino]-2H-1,2,4- triazole-3-thione (3a-o) and thioglycolic acid. The structures of all the synthesized compounds were confirmed by elemental analysis, spectral techniques like IR, 1H NMR, and mass spectroscopy. Few compounds exhibited dose-dependent cytotoxic effect in MTT assay in human breast cancer (MCF-7) cells. Apoptotic degradation of DNA due to action of potent thiazolidin-4-ones was analysed by agarose gel electrophoresis and visualized by ethidium bromide staining (comet assay). A concentration-dependent increase in tail length and olive tail moment was observed when treated with thiazolidin-4-ones. In vitro antioxidant studies like DPPH and ABTS-free radical scavenging assays-indicated moderate activity of thiazolidin-4-ones. © 2012 Springer Science+Business Media, LLC. | |
| dc.identifier.citation | Medicinal Chemistry Research, 2013, 22, 2, pp. 758-767 | |
| dc.identifier.issn | 10542523 | |
| dc.identifier.uri | https://doi.org/10.1007/s00044-012-0071-5 | |
| dc.identifier.uri | https://idr.nitk.ac.in/handle/123456789/26832 | |
| dc.subject | 2 [3 (4 chlorophenyl) 1h pyrazol 4 yl] 3 [3 mercapto 5 (2 tolyloxymethyl) 4h 1,2,4 triazol 4 yl]thiazolidin 4 one | |
| dc.subject | 2 [3 (4 chlorophenyl) 1h pyrazol 4 yl] 3 [3 mercapto 5 (4 tolyloxymethyl) 4h 1,2,4 triazol 4 yl]thiazolidin 4 one | |
| dc.subject | 2 [3 (4 chlorophenyl) 1h pyrazol 4 yl] 3 [3 mercapto 5 (phenoxymethyl) 4h 1,2,4 triazol 4 yl]thiazolidin 4 one | |
| dc.subject | 2 [3 (4 chlorophenyl) 1h pyrazol 4 yl] 3 [3 mercapto 5 [(naphthalen 1 yloxy)methyl] 4h 1,2,4 triazol 4 yl]thiazolidin 4 one | |
| dc.subject | 2 [3 (4 chlorophenyl) 1h pyrazol 4 yl] 3 [3 mercapto 5 [(naphthalen 2 yloxy)] 4h 1,2,4 triazol 4 yl]thiazolidin 4 one | |
| dc.subject | 2 [3 (4 fluorophenyl) 1h pyrazol 4 yl] 3 (3 mercapto 5 (2 tolyloxymethyl) 4h 1,2,4 triazol 4 yl]thiazolidin 4 one | |
| dc.subject | 2 [3 (4 fluorophenyl) 1h pyrazol 4 yl] 3 (3 mercapto 5 (4 tolyloxymethyl) 4H 1,2,4 triazol 4 yl]thiazolidin 4 one | |
| dc.subject | 2 [3 (4 fluorophenyl) 1h pyrazol 4 yl] 3 [3 mercapto 5 (phenoxymethyl) 4h 1,2,4 triazol 4 yl]thiazolidin 4 one | |
| dc.subject | 2 [3 (4 fluorophenyl) 1h pyrazol 4 yl] 3 [3 mercapto 5 [(naphthalen 1yloxy)]methyl] 4h 1,2,4 triazol 4 yl]thiazolidin 4 one | |
| dc.subject | 2 [3 (4 fluorophenyl) 1h pyrazol 4 yl] 3 [3 mercapto 5 [(naphthalen 2 yloxy)methyl] 4h 1,2,4 triazol 4 yl]thiazolidin 4 one | |
| dc.subject | 3 [3 mercapto 5 (2 tolyloxymethyl) 4h 1,2,4 triazol 4 yl] 2 [3 (4 methoxyphenyl) 1h pyrazol 4 yl]thiazolidin 4 one | |
| dc.subject | 3 [3 mercapto 5 (4 tolyloxymethyl) 4h 1,2,4 triazol 4 yl] 2 [3 (4 methoxyphenyl) 1h pyrazol 4 yl]thiazolidin 4 one | |
| dc.subject | 3 [3 mercapto 5 (phenoxymethyl) 4h 1,2,4 triazol 4 yl] 2 [3 (4 methoxyphenyl) 1h pyrazol 4 yl]thiazolidin 4 one | |
| dc.subject | 3 [3 mercapto 5 [(naphthalen 1 yloxy)methyl] 4h 1,2,4 triazol 4 yl] 2 [3 (4 methoxyphenyl) 1h pyrazol 4 yl]thiazolidin 4 one | |
| dc.subject | 3 [3 mercapto 5 [(naphthalen 2 yloxy)methyl] 4h 1,2,4 triazol 4 yl] 2 [3 (4 methoxyphenyl) 1h pyrazol 4 yl]thiazolidin 4 one | |
| dc.subject | antineoplastic agent | |
| dc.subject | antioxidant | |
| dc.subject | ascorbic acid | |
| dc.subject | thiazole derivative | |
| dc.subject | unclassified drug | |
| dc.subject | antineoplastic activity | |
| dc.subject | antioxidant activity | |
| dc.subject | article | |
| dc.subject | breast cancer | |
| dc.subject | cancer cell | |
| dc.subject | concentration response | |
| dc.subject | controlled study | |
| dc.subject | cytotoxicity | |
| dc.subject | DNA fragmentation | |
| dc.subject | drug bioavailability | |
| dc.subject | drug structure | |
| dc.subject | drug synthesis | |
| dc.subject | human | |
| dc.subject | human cell | |
| dc.subject | IC 50 | |
| dc.subject | infrared spectroscopy | |
| dc.subject | lipophilicity | |
| dc.subject | mass spectrometry | |
| dc.subject | polymerization | |
| dc.subject | proton nuclear magnetic resonance | |
| dc.title | Synthesis, characterization, anticancer, and antioxidant activity of some new thiazolidin-4-ones in MCF-7 cells |
